Neurological and cognitive impairment in COVID‐19: clinical characterization andepidemiological

Background COVID-19 neurological manifestations were demonstrated during the pandemic, including cognitive impairment. Objectives: To determine prevalence of and behavioral complaints (such as dementia, MCI or SCD) in a outpatient sample with recent SARS-COV2 infection. Specific: Evaluate association impairment presence polymorphism found APOE gene respiratory disease Method Observational, longitudinal, prospective clinical study. Inclusion criteria: patients confirmed Covid-19. Patients are evaluated an clinic. They through standardized attendance record, somatic assessment. Cognitive assessment involves application (ACER, MMSE CDR), functional (Pfeffer) psychiatric (GDS Beck) screening instruments, addition to subsequent extensive neuropsychological In addition, is analysed. Results date, 200 evaluated. The average age 46.5 years, 65.4% female, 79.16% 8 more years schooling, 57.5% complaints. Conclusions results so far our study demonstrate that frequent even chronic phase disease.